Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy.

Roberto Berte'Stefano MazzaMarta Rachele StefanucciDaniele NovielloStefania CostaClorinda CiafardiniErika MiletiMarina MapelliSebastiano PasqualatoSergio PintoAgnese FavaleMaurizio VecchiMarkus F NeurathRaja AtreyaMassimo Claudio FantiniFederica FacciottiFlavio Caprioli

Published in: Journal of Crohn's & colitis (2021)

Seroprevalence of SARS-CoV2 in IBD patients treated with biologic therapy reflects values measured in the local general population. Specific symptoms and contact history with SARS-CoV2-infected individuals strongly increase the likelihood of SARS-CoV2 seropositivity.

Keyphrases

sars cov
respiratory syndrome coronavirus
rheumatoid arthritis
physical activity
mesenchymal stem cells
ulcerative colitis